Table 1.
Characteristics of study participants (n = 106).
| Characteristics at baseline (N = 87–106) | n or median (% or range) |
|---|---|
| Male gender | 56 (53) |
| Gestational age (weeks) | 40 (33–42) |
| Full-term pregnancy1 | 77 (89) |
| Birth weight (g) | 3460 (1890–4670) |
| Received 3-doses vaccination course | 96 (91) |
| Received 4-doses vaccination course | 10 (9) |
| Vaccine type used for infant vaccination | |
| - monovalent vaccine | 68 (64) |
| - hexavalent vaccine | 13 (12) |
| - unknown | 25 (24) |
| Age (weeks) at vaccination | |
| - first dose | 30 (1–53) |
| - second dose | 36 (4–86) |
| - third dose | 84 (20–122) |
| - fourth dose | 85 (47–104) |
| Average time between first and third dose (weeks) | 52 (12–95) |
| Average time between second and third dose (weeks) | 43 (5–90) |
| Characteristics at follow-up (N=84–106) | |
| Age at follow-up blood sample (years) | 13.6 (10.4–16.5) |
| Chronic diseases2 | 45 (52) |
| Body mass index (kg/m2) | 19.5 (15–30) |
1
defined as gestational age >37 weeks
2
includes: endocrine and metabolic, neuropsychiatric, respiratory, orthopedic, hematologic and cardiovascular diseases, congenital malformations.